Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer

Journal of Urology

Volumn 155, Issue 4, 1996, Pages 1357-1360

  Dalkin, Bruce L ^a   Ahmann, Frederick R ^b   Nagle, Raymond ^b   Johnson, Cynthia S ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

adenocarcinoma; gonadorelin; hormones; prostatic neoplasms

Indexed keywords

ANDROGEN;

ADENOCARCINOMA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL;

EID: 0029878509     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66266-9     Document Type: Article

References (11)

1. Catalona, W. J., Richie, J. P., Ahmann, F. R., Hudson, M. A., Scardino, P. T., Flanigan, R. C., deKernion, J. B., Ratliff, T. L., Kavoussi, L. R., Dalkin, B. L., Waters, W. B., MacFarlane, M. T. and Southwick, P. C.: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of multicenter clinical trial of 6,630 men. J. Urol., 151: 1283, 1994.
2. Ehreth, J. T., Miller, J. I., McBeath, R. B., Hansen, K. K., Ahmann, F. R., Dalkin, B. L. and Schiff, M., Jr.: Prostate-specific antigen obtained under optimal conditions determines extracapsular adenocarcinoma of the prostate. Brit. J. Urol., 75: 21, 1995.
3. Hudson, M. A., Bahnson, R. R. and Catalona, W. J.: Clinical use of prostate specific antigen in patients with prostate cancer. J. Urol., 142: 1011, 1989.
4. Partin, A. W., Carter, H. B., Chan, D. W., Epstein, J. I., Oesterling, J. E., Rock, R. C., Weber, J. P. and Walsh, P. C.: Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J. Urol., 143: 747, 1990.
5. Lange, P. H., Ercole, C. J., Lightner, D. J., Fraley, E. E. and Vessella, R.: The value of serum prostate specific antigen determinations before and after radical prostatectomy. J. Urol., 141: 873, 1989.
6. Labrie, F., Cusan, L., Gomez, J. L., Diamond, P. and Suburu, R.: Down-staging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-release hormone agonist. Urol. Symposium, 44: 29, 1994.
7. Goldenberg, S. L., Klotz, L. H., Jewett, M. A. S., Srigley, J., Barkin, J., Mador, D., Fradet, Y., Chin, J. L., Paquin, J. M. and Laplante, S.: Randomized, controlled study of neoadjuvant reversible androgen withdrawal therapy with cyproterone acetate in the surgical management of localized prostate cancer. J. Urol., part 2, 153: 254A, abstract 103, 1995.
8. Soloway, M. S., Sharifi, R., Wajsman, Z., McLeod, D., Wood, D. P., Jr. and Puras-Baez for the Lupron Depot Neoadjuvant Prostate Cancer Study Group: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J. Urol., 154: 424, 1995.
9. Pedersen, K. V., Lundberg, S., Hugosson, J., Aus, G., Schelin, S., Ahlgren, G. and Abrahamsson, P.-A.: Neoadjuvant hormonal treatment with triptorelin versus no treatment prior to radical prostatectomy: a prospective randomized multicenter study. J. Urol., part 2, 153: 391A, abstract 651, 1995.
10. Ackerman, D. A., Barry, J. M., Wicklund, R. A., Olson, N. and Lowe, B. A.: Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastases at radical prostatectomy. J. Urol., 150: 1845, 1993.
11. Voges, G. E., McNeal, J. E., Redwine, E. A., Freiha, F. S. and Stamey, T. A.: Morphologic analysis of surgical margins with positive findings in prostatectomy for adenocarcinoma of the prostate. Cancer, 69: 520, 1992.